Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837306 | 0.82 | LMNA (0.53) | MAP4K4P2RX7KDM4EGAA | |
| SCHEMBL5237714 | 0.81 | HTR1A (0.51) | HTR3AKDM4EALDH1A1HRH3SMN1; SMN2 | |
| SCHEMBL4779101 | 0.80 | NPC1 (0.51) | HTR3AKDM4EALDH1A1SMN1; SMN2NCF1 | |
| SCHEMBL5317342 | 0.76 | HTR3A (0.66) | HTR3AKDM4EALDH1A1HRH3SMN1; SMN2 | |
| SCHEMBL4918026 | 0.75 | P2RX7 (0.55) | P2RX7 | |
| SCHEMBL5122944 | 0.75 | SHMT2 (0.62) | KDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL12723984 | 0.73 | HCAR2 (0.55) | HTR3AKDM4EALDH1A1SMN1; SMN2HCAR2 | |
| SCHEMBL19989300 | 0.73 | ALDH1A1 (0.50) | HTR3AKDM4EALDH1A1NCF1GAA | |
| SCHEMBL27881018 | 0.73 | MAP4K4 (0.46) | MAP4K4HTR3AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5239212 | 0.72 | KDM4E (0.68) | HTR3AKDM4EALDH1A1HRH3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| CN-1829694-A | quinoline derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2006-09-06 | — | — | CN | disclosed |
| EP-1651610-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009968-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | NQO2, RECQL, CHRM1 | MAP4K4 2927/4885HTR3A 673/4885P2RX7 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.